Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTSC+ long-term subcutaneous efgartigimod study in generalized myasthenia gravis
jRCT2021210043Phase 3Completed
- Sponsor
- argenx
- Start
- Jun 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in myasthenia gravis (MG), sponsored by argenx. Primary endpoints: Incidence and severity of adverse events, Incidence of serious adverse events and 4 more. Started Jun 2021; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021210043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210043.